Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

Key facts

Study ID

NCT00424632

Run by

Pfizer

People needed

57

Starts

2006-11-01

Expected to finish

2009-06-01

Last updated by the study team

2012-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic solid tumor resistant to standard therapy or for which no standard therapy is available
• Adequate bone marrow, liver and kidney function

You may not qualify if…

• Brain metastases that are symptomatic and/or require treatment with steroids and/or anticonvulsants, or brain metastases that have been treated within 3 months prior to study start
• Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months

Where it is running

• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Leuven, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.